LRMR Larimar Therapeutics Inc

Price (delayed)

$8.26

Market cap

$126.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.49

Enterprise value

$69.8M

Highlights
The debt has plunged by 69% YoY
The EPS has increased by 15% YoY and by 2.2% from the previous quarter
LRMR's equity has surged by 55% year-on-year but it is down by 12% since the previous quarter
LRMR's quick ratio is up by 49% year-on-year but it is down by 5% since the previous quarter
The company's net income has shrunk by 91% YoY and by 13% QoQ

Key stats

What are the main financial stats of LRMR
Market
Shares outstanding
15.37M
Market cap
$126.94M
Enterprise value
$69.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.61
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$47.9M
EBITDA
-$47.74M
Free cash flow
-$48.85M
Per share
EPS
-$3.49
Free cash flow per share
-$3.05
Book value per share
$5.13
Revenue per share
$0
TBVPS
$5.82
Balance sheet
Total assets
$93.02M
Total liabilities
$14.24M
Debt
$6.39M
Equity
$78.78M
Working capital
$77.75M
Liquidity
Debt to equity
0.08
Current ratio
10.28
Quick ratio
9.88
Net debt/EBITDA
1.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-43.8%
Return on equity
-49.9%
Return on invested capital
-226.2%
Return on capital employed
-56.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LRMR stock price

How has the Larimar Therapeutics stock price performed over time
Intraday
-1.78%
1 week
-0.84%
1 month
-37.04%
1 year
-44.93%
YTD
-61.42%
QTD
-43.46%

Financial performance

How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.24M
Net income
-$47.9M
Gross margin
N/A
Net margin
N/A
Larimar Therapeutics's operating income has shrunk by 92% YoY and by 13% QoQ
The company's net income has shrunk by 91% YoY and by 13% QoQ

Growth

What is Larimar Therapeutics's growth rate over time

Valuation

What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
1.61
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 15% YoY and by 2.2% from the previous quarter
LRMR's equity has surged by 55% year-on-year but it is down by 12% since the previous quarter
LRMR's P/B is 30% below its last 4 quarters average of 2.3 and 11% below its 5-year quarterly average of 1.8

Efficiency

How efficient is Larimar Therapeutics business performance
The ROIC has contracted by 35% from the previous quarter
Larimar Therapeutics's ROA has decreased by 20% YoY and by 8% from the previous quarter
LRMR's ROE is up by 9% year-on-year but it is down by 4.4% since the previous quarter

Dividends

What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LRMR.

Financial health

How did Larimar Therapeutics financials performed over time
The current ratio has surged by 57% year-on-year but it has declined by 6% since the previous quarter
LRMR's quick ratio is up by 49% year-on-year but it is down by 5% since the previous quarter
The debt is 92% less than the equity
LRMR's debt to equity has plunged by 80% YoY but it is up by 14% from the previous quarter
The debt has plunged by 69% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.